CuS@PDA–FA Nanocomposites: A Dual Stimuli-responsive DOX Delivery Vehicle with Ultrahigh Loading Level for Synergistic Photothermal-chemotherapies on Breast Cancer
In this study, CuS@PDA nanoparticles were synthesized and used to create a novel tumor-targeting nanocomposite platform composed of copper sulfide@polydopamine-folic acid/doxorubicin (CuS@PDA–FA/DOX) for performing both photothermal and chemotherapeutic cancer treatment. The nanocomposite platform has ultrahigh loading levels (4.2 ± 0.2 mg mg-1) and a greater photothermal conversion efficiency (η=42.7%) than CuS/PDA alone. An over expression of the folate receptor (FR) in MCF-7 cells allows for CuS@PDA–FA/DOX nanocomposites to favor interactions with them rather than non-cancerous cells that do not express the FR as readily. Under near infrared (NIR) irradiation, the CuS@PDA–FA/DOX system using a synergistic combination of photothermal therapy and chemotherapy yields a better therapeutic effect than either photothermal therapy or chemotherapy alone. The treatment is very effective with the cell viability is only 5.6 ± 1.4%.